Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs.
antipsychotic long-acting injections
health satisfaction
quality of life
relapses
schizophrenia spectrum disorders
Journal
Neuropsychiatric disease and treatment
ISSN: 1176-6328
Titre abrégé: Neuropsychiatr Dis Treat
Pays: New Zealand
ID NLM: 101240304
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
01
2022
accepted:
10
03
2022
entrez:
20
4
2022
pubmed:
21
4
2022
medline:
21
4
2022
Statut:
epublish
Résumé
Antipsychotic long-acting injections (AP-LAIs) are indicated for patients affected by schizophrenia especially those with poor treatment adherence. To compare paliperidone palmitate 3-monthly (PP3M), paliperidone palmitate one-monthly (PP1M) and haloperidol decanoate (HAL-D) treatment, we enrolled 90 patients with schizophrenia treated in Mental Health Center with one of the three AP-LAIs for at least six months and followed them for another 6 months. At 6 and 12 months of treatment we administered Clinical Global Impression-Severity, Global Assessment of Functioning and World Health Organization Quality of Life-26 items (WHOQOL-BREF). At 1-year treatment, we evaluated relapses (psychiatric hospitalizations and urgent consultations), side effects and drop-outs. We did not highlight any statistically significant difference among the three treatments in relapses and scale scores. Weight increase was significantly higher in PP1M and PP3M groups. Twelve patients (13.3%) discontinued AP-LAI. At 1-year AP-LAI treatment, 69% of patients rated quality of life as "good" or "very good" and 71% declared themselves to be "satisfied" or "very satisfied". HAL-D, PP1M and PP3M 1-year treatments were similarly effective in preventing relapses and improving quality of life and health satisfaction. All discontinuations in the new 3-monthly antipsychotic treatment were caused by patient refusal to continue it.
Identifiants
pubmed: 35440870
doi: 10.2147/NDT.S356341
pii: 356341
pmc: PMC9013412
doi:
Types de publication
Journal Article
Langues
eng
Pagination
829-846Informations de copyright
© 2022 Di Lorenzo et al.
Déclaration de conflit d'intérêts
The authors report no actual or potential conflicts of interest.
Références
Lancet. 2016 Jul 2;388(10039):86-97
pubmed: 26777917
Patient Prefer Adherence. 2020 Jun 17;14:995-1010
pubmed: 32606616
Psychiatry Res. 2017 Jan;247:257-264
pubmed: 27936437
Schizophr Res. 2011 Sep;131(1-3):127-32
pubmed: 21576008
J Med Econ. 2016;19(2):111-20
pubmed: 26414966
JAMA Psychiatry. 2017 Jul 1;74(7):686-693
pubmed: 28593216
Aust N Z J Psychiatry. 2016 May;50(5):410-72
pubmed: 27106681
Psychol Med. 1998 May;28(3):551-8
pubmed: 9626712
Int Clin Psychopharmacol. 2017 Sep;32(5):235-248
pubmed: 28430670
J Med Econ. 2018 Feb;21(2):135-143
pubmed: 28895766
Acta Psychiatr Scand. 2009 Jan;119(1):4-14
pubmed: 19133915
Schizophr Bull. 2007 Sep;33(5):1225-37
pubmed: 17204532
J Clin Psychopharmacol. 2013 Feb;33(1):80-3
pubmed: 23277247
Clin Schizophr Relat Psychoses. 2014 Jan;7(4):199-206
pubmed: 23428784
Neuropsychiatr Dis Treat. 2017 Nov 07;13:2767-2779
pubmed: 29158676
Schizophr Bull. 2013 Nov;39(6):1296-306
pubmed: 23172003
Int J Ment Health Syst. 2010 Dec 08;4:31
pubmed: 21143871
Schizophr Res. 2017 May;183:10-21
pubmed: 27866695
Schizophr Bull. 2015 May;41(3):627-36
pubmed: 25180312
BMC Psychiatry. 2018 May 29;18(1):155
pubmed: 29843676
Patient Prefer Adherence. 2020 Jul 02;14:1093-1102
pubmed: 32753849
Encephale. 2019 Dec;45(6):459-467
pubmed: 31542210
Pharmacoeconomics. 2016 Apr;34(4):363-91
pubmed: 26883132
Psychopharmacol Bull. 2017 May 15;47(2):42-52
pubmed: 28626271
Am J Psychiatry. 2011 Jun;168(6):603-9
pubmed: 21362741
J Clin Psychopharmacol. 2019 Sep/Oct;39(5):441-445
pubmed: 31415288
J Mark Access Health Policy. 2015 Sep 10;3:
pubmed: 27123183
Curr Clin Pharmacol. 2014;9(3):310-7
pubmed: 23343447
JAMA. 2014 May 21;311(19):1978-87
pubmed: 24846035
Psychol Med. 2018 Jul;48(10):1616-1623
pubmed: 29039277
Curr Med Res Opin. 2021 Apr;37(4):665-674
pubmed: 33507831
J Clin Psychiatry. 2019 Sep 17;80(5):
pubmed: 31536686
Neuropsychiatr Dis Treat. 2018 Sep 17;14:2361-2366
pubmed: 30271152
PLoS One. 2017 Jun 14;12(6):e0179049
pubmed: 28614404
J Clin Psychiatry. 2013 Sep;74(9):e18
pubmed: 24107769
Am J Psychiatry. 2002 Apr;159(4):554-60
pubmed: 11925292
Molecules. 2018 Aug 20;23(8):
pubmed: 30127324
Ther Adv Psychopharmacol. 2020 May 25;10:2045125320926347
pubmed: 32518617
Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):343-9
pubmed: 23763531
Lancet. 2012 Jun 2;379(9831):2063-71
pubmed: 22560607
Clin Drug Investig. 2021 Jan;41(1):99-113
pubmed: 33331979
J Clin Psychiatry. 2013 Oct;74(10):957-65
pubmed: 24229745
J Manag Care Spec Pharm. 2018 Aug;24(8):759-768
pubmed: 30058979
J Psychiatr Res. 2020 Oct;129:222-233
pubmed: 32805530
Curr Med Res Opin. 2019 Mar;35(3):407-416
pubmed: 30556739
Hum Psychopharmacol. 2020 May;35(3):e2729
pubmed: 32182388
Psychiatry (Edgmont). 2007 Jul;4(7):28-37
pubmed: 20526405
Ment Health Clin. 2018 Mar 26;8(2):56-62
pubmed: 29955546
Am J Psychiatry. 2002 Jan;159(1):103-8
pubmed: 11772697
Schizophr Bull. 2018 Oct 17;44(6):1195-1203
pubmed: 29762765
Clin Drug Investig. 2020 Apr;40(4):355-375
pubmed: 32152867
Schizophr Res. 2015 Dec;169(1-3):400-405
pubmed: 26395153
Int J Psychiatry Clin Pract. 2021 Sep;25(3):238-244
pubmed: 33555218
Eur Psychiatry. 2016 Sep;37:43-8
pubmed: 27447102
Nord J Psychiatry. 2018 Apr;72(3):214-220
pubmed: 29278968
Pharmacoecon Open. 2019 Jun;3(2):177-188
pubmed: 30088229
Am J Psychiatry. 2004 Feb;161(2 Suppl):1-56
pubmed: 15000267
Am J Geriatr Psychiatry. 2020 Jan;28(1):23-30
pubmed: 31481273
BMC Psychiatry. 2013 May 30;13:155
pubmed: 23718192
Neuropsychiatr Dis Treat. 2019 Apr 30;15:1045-1060
pubmed: 31118640
J Clin Psychiatry. 2003;64 Suppl 16:18-23
pubmed: 14680415
Curr Treat Options Psychiatry. 2017;4(2):117-126
pubmed: 28580230
Int J Neuropsychopharmacol. 2016 Jul 05;19(7):
pubmed: 26902950
Schizophr Res. 2015 Oct;168(1-2):498-504
pubmed: 26232241
Psychiatr Q. 2019 Sep;90(3):519-532
pubmed: 31119453
Am J Psychiatry. 1992 Sep;149(9):1148-56
pubmed: 1386964
Curr Health Sci J. 2018 Apr-Jun;44(2):122-128
pubmed: 30746158
J Clin Psychiatry. 2020 Mar 24;81(2):
pubmed: 32237296
J Clin Psychiatry. 2016 Jun;77(6):764-71
pubmed: 27135986
J Med Econ. 2018 Feb;21(2):127-134
pubmed: 28895758
Clin Ther. 2021 Mar;43(3):535-548
pubmed: 33589216
Neuropsychiatr Dis Treat. 2019 Jan 07;15:183-198
pubmed: 30662264
J Clin Psychopharmacol. 2020 Jul/Aug;40(4):346-349
pubmed: 32639287
Schizophr Res. 2017 Jul;185:96-100
pubmed: 28119036
Ther Adv Psychopharmacol. 2018 Sep 25;8(12):333-336
pubmed: 30524701
Ann Agric Environ Med. 2018 Mar 14;25(1):50-55
pubmed: 29575877